Electronics manufacturing services provider Flextronics will help design and manufacture Ichor Medical Systems’ next-generation TriGrid DNA Delivery System for cancer vaccines and treatment of various diseases.
TriGrid technology has recently been licensed by Pfizer for the intracellular delivery of its DNA-based cancer vaccines.
Mark Kemp, president of Flextronics’ medical group, said with TriGrid’s electroporation technology, a wide range of promising DNA-based therapies can now be made much more effective. “We look forward to helping them develop their product, from design to delivery,” he said.
Supply chain services for this next-generation TriGrid system will be performed at Flextronics facilities in Texas. Flextronics engineers will work with Ichor staff to develop and build the electronic and mechanical components of the device.
Ichor’s patented TriGrid Delivery System is the first integrated and fully automated device for electroporation-mediated DNA administration in humans. Electroporation is a method for enhancing DNA vaccine delivery that uses electrical fields at the site of DNA administration, resulting in increased antigen expression and enhanced immune responses to the encoded antigen, according to Ichor.
“Ichor is pleased to partner with a global organization like Flextronics,” said Ichor CEO Bob Bernard. He said the EMS provider will help Ichor move to “rapid and scalable commercialization of the next-generation TriGrid DNA-based therapeutic products.”
Flextronics is headquartered in Singapore and Ichor is based in San Diego.